About: Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis
Creator	Yang, Jing Zheng, Ya Chen, Zhaofeng Gou, Xi Guo, Qinghong Ji, Rui Pu, Ke Wang, Haojia Wang, Yuping Zhou, Yongning
Source	Elsevier; Medline; PMC; WHO
abstract	BACKGROUND: An outbreak of coronavirus disease 2019 (COVID-19) occurred in Wuhan, China; the epidemic is more widespread than initially estimated, with cases now confirmed in multiple countries. AIMS: The aim of this meta-analysis was to assess the prevalence of comorbidities in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infected patients and the risk of underlying diseases in severe patients compared to non-severe patients. METHODS: A literature search was conducted using the databases PubMed, EMBASE, and Web of Science through February 25, 2020. Odds ratios (ORs) and 95% confidence intervals (CIs) were pooled using random-effects models. RESULTS: Seven studies were included in the meta-analysis, including 1 576 infected patients. The results showed the most prevalent clinical symptom was fever (91.3%, 95% CI: 86–97%), followed by cough (67.7%, 95% CI: 59–76%), fatigue (51.0%, 95% CI: 34–68%) and dyspnea (30.4%, 95% CI: 21–40%). The most prevalent comorbidities were hypertension (21.1%, 95% CI: 13.0–27.2%) and diabetes (9.7%, 95% CI: 7.2–12.2%), followed by cardiovascular disease (8.4%, 95% CI: 3.8–13.8%) and respiratory system disease (1.5%, 95% CI: 0.9–2.1%). When compared between severe and non-severe patients, the pooled OR of hypertension, respiratory system disease, and cardiovascular disease were 2.36 (95% CI: 1.46–3.83), 2.46 (95% CI: 1.76–3.44) and 3.42 (95% CI: 1.88–6.22) respectively. CONCLUSION: We assessed the prevalence of comorbidities in the COVID-19 patients and found that underlying disease, including hypertension, respiratory system disease and cardiovascular disease, may be risk factors for severe patients compared with non-severe patients.
has issue date	2020-03-12(xsd:dateTime)
bibo:doi	10.1016/j.ijid.2020.03.017
bibo:pmid	32173574
has license	no-cc
sha1sum (hex)	d6c866d55195b1ebc52d61037c2154016aa565cb
schema:url	https://doi.org/10.1016/j.ijid.2020.03.017
resource representing a document's title	Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis
has PubMed Central identifier	PMC7194638
has PubMed identifier	32173574
schema:publication	Int J Infect Dis
resource representing a document's body	covid:d6c866d55195b1ebc52d61037c2154016aa565cb#body_text
is schema:about of	named entity 'estimated' named entity 'patients' named entity 'severe' named entity 'Web' named entity 'models' named entity 'When' named entity 'patients' named entity 'prevalence' named entity 'fever' named entity 'February 25' named entity '95% CI' named entity 'risk' named entity 'SCIENCE' named entity 'WUHAN' named entity '2851' named entity 'FATIGUE' named entity 'HYPERTENSION' named entity 'PATIENTS' named entity '1.88' named entity 'INCLUDED' named entity 'INCLUDING' named entity 'COUNTRIES' named entity 'CONFIDENCE INTERVALS' named entity 'CLINICAL SYMPTOM' named entity 'PUBMED' named entity 'BACKGROUND' named entity 'CHINA' named entity 'DYSPNEA' covid:arg/d6c866d55195b1ebc52d61037c2154016aa565cb named entity 'comorbidities' named entity 'prevalent' named entity '95% CI' named entity '95% CI' named entity 'Background' named entity 'Methods' named entity 'meta-analysis' named entity 'patients' named entity 'cardiovascular disease' named entity 'COVID-19' named entity 'hypertension' named entity 'prevalence' named entity '95% CI' named entity 'Conclusion' named entity 'severe' named entity 'comorbidities' named entity 'patients' named entity 'comorbidities' named entity 'Web of Science' named entity 'Wuhan' named entity 'fever' named entity '95% CI' named entity 'cardiovascular disease' named entity 'cardiovascular disease' named entity 'hypertension' named entity 'diabetes' named entity '68%' named entity 'PubMed' named entity 'comorbidities' named entity 'hypertension' named entity 'ratios' named entity 'hypertension' named entity 'COVID-19' named entity 'people with diabetes' named entity 'National Health Commission' named entity 'confidence intervals' named entity '95% CI' named entity 'viruses' named entity 'infectious disorders' named entity 'EMBASE' named entity 'inclusion and exclusion criteria' named entity 'Coronavirus' named entity 'MERS-CoV'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software